Enteroendocrine L cell: difference between revisions
Diff·revision 38 → 39·18:01, 14 Jun 2025
Difference between revision 38 and revision 39 of Enteroendocrine L cell. 3 lines changed; the page grew by 435 bytes.
| Revision 38 — 22:08, 2 Jun 2025 StubSorterBot (talk) bot: update parent category chain 4,648 bytes ±0 | Revision 39 — 18:01, 14 Jun 2025 ReceptorRhoda (talk) correct percentage: source reports placebo-adjusted 5,083 bytes +435 | ||
|---|---|---|---|
| 20 | L cells are continuously regenerated from intestinal stem cells in the intestinal crypts, with a typical lifespan of 3–5 days for a mature L cell. Factors influencing L-cell differentiation include specific transcription-factor pathways, growth factors from neighbouring cells, and signalling molecules from the microbiota.{{r|biemin2019}} | 20 | L cells are continuously regenerated from intestinal stem cells in the intestinal crypts, with a typical lifespan of 3–5 days for a mature L cell. Factors influencing L-cell differentiation include specific transcription-factor pathways, growth factors from neighbouring cells, and signalling molecules from the microbiota.{{r|biemin2019}} |
| 21 | 21 | ||
| + | 22 | == Clinical significance == | |
| + | 23 | L cells are the primary target of [[GLP-1 receptor agonist|GLP-1-directed therapeutics]], which work by mimicking or enhancing the action of GLP-1 released from these cells. Understanding L-cell biology has informed drug development and has identified therapeutic opportunities for enhancing endogenous GLP-1 secretion or L-cell mass expansion, approaches currently under investigation in clinical trials. | |
| + | 24 | ||
| 22 | == References == | 25 | == References == |
| 23 | {{reflist}} | 26 | {{reflist}} |